in a personal controlled , prospective , randomezed trial comparing subcutaneous heparin and intravenous dextran 40 , 35.8 per cent of the controls ( n=95 ) , 13.2 per cent of the 83 patients in the heparin group , and 20.5 per cent in the dextran group ( n=83 ) developed deep venous thrombosis .
C0011793
dextran 40
C0086140
dextran